These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26193849)

  • 1. Mind the gap: An empirical study of post-trial access in HIV biomedical prevention trials.
    Haire B; Jordens C
    Dev World Bioeth; 2015 Aug; 15(2):85-97. PubMed ID: 26193849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Because we can: clashes of perspective over researcher obligation in the failed PrEP trials.
    Haire BG
    Dev World Bioeth; 2011 Aug; 11(2):63-74. PubMed ID: 21266000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-trial access to antiretrovirals: who owes what to whom?
    Millum J
    Bioethics; 2011 Mar; 25(3):145-54. PubMed ID: 19594728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microbicide research in developing countries: have we given the ethical concerns due consideration?
    Moodley K
    BMC Med Ethics; 2007 Sep; 8():10. PubMed ID: 17877834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reciprocity and post-trial access for participants in antiretroviral therapy trials.
    Merritt M; Grady C
    AIDS; 2006 Sep; 20(14):1791-4. PubMed ID: 16954719
    [No Abstract]   [Full Text] [Related]  

  • 6. Access to treatment in HIV prevention trials: perspectives from a South African community.
    Barsdorf N; Maman S; Kass N; Slack C
    Dev World Bioeth; 2010 Aug; 10(2):78-87. PubMed ID: 19793135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The obligation to provide antiretroviral treatment in HIV prevention trials.
    Lo B; Padian N; Barnes M
    AIDS; 2007 Jun; 21(10):1229-31. PubMed ID: 17545698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment needs in HIV prevention trials: using beneficence to clarify sponsor-investigator responsibilities.
    Stobie M; Slack C
    Dev World Bioeth; 2010 Dec; 10(3):150-7. PubMed ID: 20002648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethics of medical care and clinical research: a qualitative study of principal investigators in biomedical HIV prevention research.
    Haire BG
    J Med Ethics; 2013 Apr; 39(4):231-5. PubMed ID: 23175459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stakeholder perspectives on ethical challenges in HIV vaccine trials in South Africa.
    Essack Z; Koen J; Barsdorf N; Slack C; Quayle M; Milford C; Lindegger G; Ranchod C; Mukuka R
    Dev World Bioeth; 2010 Apr; 10(1):11-21. PubMed ID: 19459900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementing post-trial access plans for HIV prevention research.
    Paul A; Merritt MW; Sugarman J
    J Med Ethics; 2018 May; 44(5):354-358. PubMed ID: 29487116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Provision of HIV treatment in HIV preventive vaccine trials: a developing country perspective.
    Slack C; Stobie M; Milford C; Lindegger G; Wassenaar D; Strode A; Ijsselmuiden C
    Soc Sci Med; 2005 Mar; 60(6):1197-208. PubMed ID: 15626517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges with participant reimbursement: experiences from a post-trial access study.
    Mngadi KT; Frohlich J; Montague C; Singh J; Nkomonde N; Mvandaba N; Ntombeka F; Luthuli L; Abdool Karim Q; Mansoor L
    J Med Ethics; 2015 Nov; 41(11):909-13. PubMed ID: 26392172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Standards of care in the antiretroviral rollout world.
    Singh JA
    Lancet; 2004 Sep 11-17; 364(9438):920-2. PubMed ID: 15364176
    [No Abstract]   [Full Text] [Related]  

  • 15. Ethics of ancillary care in clinical trials in low income countries: a Nigerian case study.
    Haire BG; Ogundokun O
    Afr J Reprod Health; 2014 Sep; 18(3 Spec No):135-42. PubMed ID: 26050386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-trial access to study medication: a Brazilian e-survey with major stakeholders in clinical research.
    Dainesi SM; Goldbaum M
    J Med Ethics; 2012 Dec; 38(12):757-62. PubMed ID: 22915826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forthcoming practical framework for ethics committees and researchers on post-trial access to the trial intervention and healthcare.
    Sofaer N; Lewis P; Davies H
    J Med Ethics; 2014 Apr; 40(4):217-8. PubMed ID: 23645524
    [No Abstract]   [Full Text] [Related]  

  • 18. Equitable treatment for HIV/AIDS clinical trial participants: a focus group study of patients, clinician researchers, and administrators in Western Kenya.
    Shaffer DN; Yebei VN; Ballidawa JB; Sidle JE; Greene JY; Meslin EM; Kimaiyo SJ; Tierney WM
    J Med Ethics; 2006 Jan; 32(1):55-60. PubMed ID: 16373525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should post-trial provision of beneficial experimental interventions be mandatory in developing countries?
    Zong Z
    J Med Ethics; 2008 Mar; 34(3):188-92. PubMed ID: 18316461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How Bioethics is Complementing Human Rights in Realizing Health Access for Clinical Trial Participants: The Case of Formative PrEP Access in South Africa.
    Singh J
    Health Hum Rights; 2015 Jun; 17(1):E58-62. PubMed ID: 26204584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.